EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia

Lance A. Williams, Jill Adamski, Theresa N. Kinard, Natalie M. Ertz‐Archambault, Qun Lu, Kristin Gray, Jennifer L. Herrick, Leon Su, Leslie Padrnos

Journal of Clinical Apheresis · 2023-12 · 38 (6) · 755-759

DOI: 10.1002/jca.22086 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract This manuscript describes a novel approach for treating patients with long‐term sequelae from hemoglobin Evans (Hb Evans). After instituting conservative therapies for approximately 2 years, our patient's symptoms continually worsened. Therefore, we performed red blood cell exchange (RBCx) to reduce his Hb Evans percentage and his co‐existing elevation of methemoglobin. Our assumptions of clinical benefit were based on our collective experience performing RBCx for patients with sickle cell disease. After the first exchange, pre‐ and post‐laboratory results supported our approach and the patient experienced marked improvement in his clinical signs and symptoms. This report provides preliminary proof of principle for the use of RBCx to treat Hb Evans and other non‐Hb S hemoglobinopathies.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →